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Abstract
Background: Freezing rate of second-generation cryoballoon (CB) is a biophysical 
parameter that could assist pulmonary vein isolation. The aim of this study is to assess 
freezing rate (time to reach –30°C ([TT-30C]) as an early predictor of acute pulmonary 
vein isolation using the CB. 
Methods: Biophysical data from CB freeze applications within a multicenter, nation-wide 
CB ablation registry were gathered. Successful application (SA), was defined as achieving 
durable intraprocedural vein isolation with time to isolation in under 60 s (SA-TTI<60) as 
achieving durable vein isolation in under 60 s. Logistic regressions were performed and 
predictive models were built for the data set. 
Results: 12,488 CB applications from 1,733 atrial fibrillation (AF) ablation procedures 
were included within 27 centers from a Spanish CB AF ablation registry. SA was achieved 
in 6,349 of 9,178 (69.2%) total freeze applications, and SA-TTI<60 was obtained in 2,673 
of 4,784 (55.9%) freezes and electrogram monitoring was present. TT-30C was shorter in 
the SA group (33.4  9.2 vs 39.3  12.1 s; p < 0.001) and SA-TTI<60 group (31.8  7.6 vs. 
38.5  11.5 s; p < 0.001). Also, a 10 s increase in TT-30C was associated with a 41% 
reduction in the odds for an SA (odds ratio [OR] 0.59; 95% confidence interval [CI] 0.56–
0.63) and a 57% reduction in the odds for achieving SA-TTI<60 (OR 0.43; 95% CI 0.39–
0.49), when corrected for electrogram visualization, vein position, and application order. 
Conclusions: Time to reach –30°C is an early predictor of the quality of a CB application 
and can be used to guide the ablation procedure even in the absence of electrogram 
monitoring.  
Key words: cryoballoon ablation, second-generation cryoballoon, atrial fibrillation, 
pulmonary vein isolation, atrial fibrillation ablation
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Introduction
Pulmonary vein isolation (PVI) using a second generation cryoballoon (CB) 
catheter (Arctic Front Advance, Medtronic Inc.) has become a widespread procedure for the
treatment of patients with atrial fibrillation (AF) [1, 2]. Two cryoballoon-specific 
procedural guidelines were published with practical recommendations on operator-
controlled parameters for dosing and monitoring [3, 4]. Important parameters related to 
tissue injury and procedure efficacy are balloon-to-vein occlusion, freezing rate, balloon 
nadir temperature (NT), visibility of vein potentials and real-time isolation monitoring, 
balloon thawing time, and total freezing time. Studies have observed that a longer time-to-
isolation (TTI) during a freeze is a predictor of vein reconnection during follow-up [5–7], 
and a target of a TTI in under 60 s (TTI<60) is recommended [4]. A more specific 
evaluation determined that the time to reach –40°C balloon temperature (when longer than 
60 s) is an independent multivariate predictor of vein reconnection [5]. Furthermore, the 
CIRCA-DOSE trial protocol recommends to stop an application after 60 s of freezing if no 
vein isolation is achieved or the CB has not reached –35°C [8]. Notably, the time to reach –
30°C (TT-30C) is a parameter that indicates the rate of freezing and is potentially related to 
the quality of occlusion and vein reconnection [9]. Thus, the aim of this study was to assess




The Spanish Registry of Cryoballoon Ablation (RECABA) (NCT02785991) is a 
prospective registry used to monitor the treatment of patients with AF when undergoing a 
CB catheter ablation. This RECABA registry included 1,745 patients at 27 centers in Spain,
from September 2016 to January 2019. Each center selected patients with an indication of 
AF ablation and followed their local CB ablation practice(s). The study protocol was 
validated by local ethics committees, and patients signed an informed consent upon 
inclusion. The study followed the general principles outlined in the Declaration of Helsinki.
There were no predefined target ablation parameters nor established cryoablation dose(s) 
per application. The acute intraprocedural efficacy endpoint was the isolation of all 
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pulmonary veins (PVs). Procedures were performed using an Arctic Front Advanced CB 
(Medtronic, Inc.), and only 28-mm cryoballoon procedures were included in this analysis (n
= 1,733). 
Cryoballoon ablation
The descriptions of a CB ablation have been previously described in detail [1, 2]. 
During the RECABA collection each center used their own standard-of-care practices 
during the procedure. In general, subjects were sedated by either general anesthesia or 
conscious sedation. A transseptal needle puncture for left atrial access was immediately 
followed by heparin bolus delivery. Subsequent heparin delivery was administered while 
monitoring activated clotting time. A purpose-built dedicated delivery sheath (FlexCath or 
FlexCath Advance; Medtronic, Inc.) was used to advance the CB catheter during the 
procedure. Cryoablations were conducted with a 28-mm CB which was delivered by an 
over-a-wire method in the left atrium. Freeze applications and length of individual freezes 
were determined by the center’s standard-of-care usage. Operators were using a dedicated 
inner-lumen diagnostic catheter (Achieve or Achieve Advance; Medtronic, Inc.) to record 
real-time PV electrograms during freeze application. Post-ablation testing methods were 
left to the discretion of the operator; however, acute durable PVI was the intraprocedural 
endpoint which was consistently defined as electrical conduction isolation confirmed by 
pace-block testing. 
Measured parameters
RECABA recorded several variables with regards to CB-related parameters utilized 
during PVI, including: 1) PV location, 2) TT-30C denoted as the time in seconds from the 
beginning of the freeze application until the cryoballoon reached –30°C, 3) visibility of 
electrogram which was recorded as the presence of a PV electrogram during the 
application, 4) TTI denoted as the time from the beginning of the freeze until the 
disappearance of PV electrograms, indicating entry block, 5) Temperature at isolation (TAI)
which was the temperature (°C) of the CB when acute isolation was achieved, 6) balloon 
NT was recorded as the lowest temperature (°C) achieved by the CB during the application,
7) cryoballoon dose (CBD) was reported as the time from the beginning of the freeze until 
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its termination, 8) balloon thaw time was denoted from the time of freeze termination until 
the balloon reached +20°C, and 9) acute PVI which was recorded as the elimination of PV 
electrograms at the end of the application. Data on continuous application parameters were 
cleaned by excluding values below and above the 1st and 99th percentiles, respectively. 
Application parameters with conflicting data (likely due to data entry errors) were excluded
from evaluation in this study.
Successful applications (SA) were denoted as achieving durable vein isolation after 
a complete application with or without live electrogram monitoring which was confirmed 
by entrance and/or  exit block. Conversely, failed applications (FA) were recorded as a 
failure to achieve vein isolation with or without electrogram monitoring. This category 
included acute reconnections, as applications where isolation was achieved but the cardiac-
to-PV electrograms resumed after cryoballoon thawing. In some cases, a bonus freeze (one 
additional freeze beyond established and proven PVI) was used because of physician 
preference, but those were not taken into consideration in this analysis. Consequently, the 
first established endpoint was defined as SA or FA. Because TTI<60 is an established 
freeze parameter for predicting durable PVI, the RECABA study also evaluated this 
variable with regards to intraprocedural SA or FA. Thus, there were two categories of 
TTI<60. In SA-TTI<60 applications, a freeze had visible real-time electrograms, and TTI 
was achieved in under 60 s with durable intraprocedural PVI. In an FA-TTI<60, there was 
either a failure during real-time electrogram recording, or an acute isolation whereby TTI 
took longer than 60 s.
Statistical analysis
Associations between SA and SA-TTI<60 and biophysical parameters were 
investigated using logistic regression and building receiver operating characteristic (ROC) 
curves. Both SA and SA-TTI<60 were used as dichotomous criteria (success or failure). 
Biophysical variables (vein location, type of vein, etc.) and procedure parameters (TT-30C, 
NT, etc.) were used as possible explanatory predictors. Standard errors from regression 
models were adjusted clustering applications by patient. Differences in the model 
goodness-of-fit chi-square statistic (Δχ2) and resulting ROC curves and associated statistics 
were used to compare models. An all-possible-combination approach was used, while 
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fixing TT-30C and selecting the model based on the area under the curve (AUC). AUC 
values between different models were compared seeking maximum parsimony without a 
significant decrease in the AUC in order to select the final model. A table with predicted 
probabilities for the endpoint was constructed for a set of values for the variables in the 
model. T-tests were used to analyze continuous data where appropriate. Associations 
between observed TT-30C and other continuous variables were assessed using the 
Pearson’s correlation and linear regression models. Classical transformations were 
performed seeking the best fitting power. 
Analyses were performed in STATA statistical software (StataCorp LLC) advised by
an independent statistician. Statistical significance was assumed for two-sided p-values 
below 0.05.
Results
In total, 1,733 patients from 27 Spanish centers were included between September 
2016 and January 2019. Within the data collection, 1,202 (68.9%) were men, and the mean 
age was 58.01 ± 10.41 years. Baseline characteristics are summarized in Table 1. A total of 
12,448 CB applications were reported in 6,694 veins from 1,733 patients. Up to 376 (3%) 
were not classified due to inconsistent data, leaving 12,072 applications from 1,722 
patients. The mean number of applications per procedure was 7.18  2.7, and the mean 
freeze applications per vein was 1.9  1.1. 
Overall, 4,601 (37.4%) freezes applied a 180 s dose, and 3,740 (30.4%) freezes 
applied a 240 s dose. Operators applied 2,995 bonus freeze applications (CB application 
after achieving vein isolation) in 2,569 (38.4%) veins from 1,097 (63.3%) patients. Vein 
electrograms were monitored in 5,046 (53.31%) non-bonus applications, and TT-30C was 
recorded in 9,827 applications. A total of 6,349 of 9,178 freeze applications were successful
(SA = 69.2%), and 2,673 of 4,784 applications achieved TTI<60 (SA-TTI<60 = 55.9%, 
Fig. 1). Overall, the mean TT-30C was 35.05  10.4 s. In the SA group, the mean TT-30C 
was 33.4  9.2 vs. 39.3  12.1 s in the FA group (t test = –22.0, p < 0.001), and 31.8  7.6 
vs. 38.6  11.5 s for the SA-TTI<60 and FA-TTI<60 groups, respectively (t test = –22.3, p 
< 0.001). 
6
Time to reach –30°C did not differ between right or left-sided applications. From 
9,827 applications, the average TT-30 for right veins was 34.8  10.8 vs. 34.5  10.2 s for 
left ones (t-test = 1.6, p = 0.11). 
There was also no relationship between phrenic nerve palsy and TT-30C in RSPV. 
From 1,374 patients with TT-30C data on RSPV application, 36 presented phrenic nerve 
palsy. Mean TT-30 was 30.13  8.9 s in the control group and 27.8  6.1 seconds in the 
phrenic nerve palsy group, (t-test = 1.52, p = 0.13). 
Univariate logistic regression models for different biophysical parameters showed 
different AUCs (Table 2). Thaw time and balloon NT were better predictors of SA (Δχ2 = 
479.8, p < 0.001) than TT-30C. However, TT-30C tended to be a better predictor of SA-
TTI<60 than the other two variables, but without statistically significant differences 
between the three variables (Δχ2 = 4.9, p = 0.09). Multivariate logistic models included TT-
30C, visualization of PV electrograms, first vs. successive freeze applications in the same 
vein and the type of PV (superior, intermediate, inferior, or common trunk) as predictors for
acute intraprocedural isolation success. Estimates for the multivariate models are shown in 
Figure 2.
Time to reach –30°C, PV electrogram visualization, first application, and inferior or 
intermediate vein were independent predictors for SA. In the multivariate model, a 10 s 
increase in TT-30C entailed an odds ratio (OR) of 0.58 (95% confidence interval [CI] 0.54–
0.62) for SA. Compared to superior veins, inferior and intermediate veins had a statistically
significant effect. This model was compared with a simplified one omitting the type of 
vein, finding no statistically significant differences between the AUCs (0.7332 [95% CI 
0.72–0.75] vs. 0.7301 [95% CI 0.72–0.74]; Δχ2 = 5.41, p = 0.02).  
Logistic regression models for predicting SA-TTI<60 included TT-30C, first vs 
successive applications in the same vein and the type of vein. Electrogram visualization 
was discarded since all applications considered had electrogram monitoring (Fig. 3). TT-
30C, first application and common trunk were independent predictors of SA-TTI<60. A 10-
s increase in TT-30C entailed an OR 0.43 (95% CI 0.39–0.49) for SA-TTI<60. The two-
variable model achieved an AUC 0.7326 (95% CI 0.72–0.75). Figure 4 depicts the 
probability of achieving SA-TTI<60 for different values of TT-30C and applications. The 
optimal cutoff point based on the ROC curve was a predicted probability of 60.3% for SA-
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TTI<60, with sensitivity = 68.6% (95% CI 66.7–70.5%) and specificity = 66.7% (64.4–
68.9%).
The (TT-30C and balloon NT) scatter plot showed a non-linear relationship between
TT-30C and NT (Fig. 5). Classical transformations showed an inverse relationship between 
TT-30C and balloon NT. A multivariable linear regression model predicting NT considered 
9,453 freeze applications in 1,418 procedures (including SA, FA, and bonus applications). 
In the total examination, 1/TT-30C was the best single predictor of balloon NT. The final 
model reached an adjusted-R2 = 0.53. Additionally, CB dose, vein type (inferior or 
intermediate vs. superior), first freeze application, bonus freeze application, and PV 
electrogram visualization were also independent predictors of balloon NT (Fig. 6). Figure 5
depicts the relationship between balloon NT, TT-30C, SA, and SA-TTI<60.  
Discussion 
According to available research, RECABA is the largest cryoablation registry that 
includes biophysical parameters for each CB freeze application. In the present analysis, the 
relationship was quantified between freezing rate (TT-30C) and established quality markers
of a CB application, such as SA-TTI<60, and balloon NT. Specifically, a TT-30C of 30 s in 
a first freeze application predicted a 71.7% probability of SA-TTI<60 (95% CI 68.4–
74.7%) with a sensitivity of 44.5%, specificity 80.9%, positive predictive value 82.0%, and 
negative predictive value of 42.7%. This finding could be of critical importance, since an 
early indicator of a poor-intraprocedural outcome may lead the operator to either perform a 
maneuver such as “pull-down” or to reposition the CB and continue with a new freeze 
attempt. 
Since the early days of CB ablation, there has been an interest in optimizing the 
procedure by identifying biophysical parameters from an application and clarifying their 
relationship with the application’s effectiveness. In 2011, Fürnkranz et al. [10] established 
the relationship between balloon NT and acute vein isolation using the first-generation CB. 
In that study, a NT below –51°C was unequivocally associated with vein isolation. In the 
following years, studies have examined patients with AF recurrences that underwent a 
second AF ablation procedure. Those studies compared biophysical parameters between 
reconnected and isolated veins. Ghosh et al. [9] observed that thawing time, balloon NT, the
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grade of occlusion, and freezing rate (time from 0°C to –30°C) were all predictors of PV 
reconnection and that thawing time, vein diameter, and grade of occlusion were 
independent predictors in the multivariate model. Those procedures were performed using 
the first-generation CB, and for every 10 s of freezing from 0°C to –30°C, the OR for PV 
reconnection was 1.58 (1.03–2.43; p < 0.037).
With the second-generation CB and use of a spiral catheter (Achieve, Medtronic 
Inc.); researchers have found the of the quality of the freeze application rather than the 
quantity (cryoablation dose) to be of most importance. The TTI was proven to be a marker 
of the quality and related to less PV reconnections in repeat ablation procedures [5, 7, 10]. 
Thus, TTI < 60 s has traditionally been established as a general intraprocedural parameter 
target. Moreover, the CryoDosing study evaluated a TTI-guided protocol [12]. In the 
CryoDosing study, if a TTI under 60 s was achieved, then the total dose was TTI + 120 s. 
Additionally, if TTI was between 60 and 90 s, a bonus application took place. Finally, if the
isolation was not achieved in 90 s, the application was stopped. This study proved that a 
uniform dosing strategy (using TTI) could be used successfully in a multicenter study, and 
it demonstrated that TTI-dosing could deliver long-term durable outcomes. In the CIRCA-
Dose study, an application was interrupted if within 60 s neither vein isolation nor -35°C 
were reached [8]. Also, the ICE-T study protocol established that an application would be 
stopped if isolation was not achieved in 90 s [13]. Therefore, there exist quality standards 
from trials for freeze application termination which are widely used in clinical practice. 
However, an extensive evaluation of intraprocedural parameters that predict acute PVI has 
not been evaluated in a large registry format that encompasses several real-world 
cryoablation techniques in order to obtain vastly generalizable results.
Intraprocedural parameter finding in RECABA 
The present study evaluated the relationship between TT-30C and the effectiveness 
of a CB freeze application(s). The model established the importance of freezing rate (TT-
30C) as an early predictor of efficacy. Other biophysical parameters, such as thawing time 
and balloon NT, showed a stronger association with intraprocedural success. However, 
those are final parameters instead of predictive ones. Specifically, NT and thaw time cannot
actively inform the quality of a freeze (early within the application).
9
The effect of TT-30C on intraprocedural acute efficacy can be explained by the 
close relationship between balloon-vein coupling, freezing rate, and NT. Another predictor 
of acute efficacy was the PV electrogram monitoring during the application. This could be 
explained by veins with no electrogram visualization tending to be more difficult to couple. 
Thus, the ablation requires a deeper progression of the spiral catheter to gain stability. 
Nevertheless, the OR for SA suggests that for every 10 s of TT-30C in the vein without 
electrogram visualization corrected by the application order was 0.64 (95% CI 0.58–0.70), 
which confirms this relationship (and validates TT-30C as a guidance parameter in veins 
lacking electrogram visualization). Therefore, in veins without the possibility of monitoring
real-time isolation, TT-30C should be considered. 
It is when predicting isolation under 60 s where TT-30C is more relevant. In the 
univariate analysis, TT-30C tends to be a better predictor of SA-TTI<60 than thawing time 
or NT. This can be explained by SA-TTI<60 and TT-30C both being variables that are time-
driven. Furthermore, NT and thawing time are related to the success of an application, but 
their values are known only after the application is completed. This model allows us to 
establish cutoff points within TT-30C that could guide the operator during an application. If
in a first application the CB has not reached –30°C in 40 s and 50 s, the probability to 
isolate the PV in under 60 s falls to 51% and 32%, respectively.  
Cryoballoon ablation maneuvers such as “pull-down” are performed after 60 s of 
freezing and the recommendation is to stop the application if it fails to isolate or to drop 
temperature within 20 s [14]. The use of these techniques, particularly in difficult 
anatomies, fall out of our models and therefore the present recommendations do not apply.
Clinical implications
The freezing rate as TT-30C was shown to be an early biophysical parameter, 
together with isolation in under 60 s, that could be used to stop a low-quality application 
and guide the procedure. Its usefulness is even greater in veins without electrogram 
monitoring, where it could be used to stop a suboptimal application or even avoid a bonus 
freezing. This last consideration ought to be prospectively assessed before its 
implementation. 
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Limitations of the study
The main limitation of the current study is that the origin of the data is a multicenter
registry, in which each center followed different protocols depending on its local practice 
and where some errors may have occurred during recording of the procedure data. 
Additionally, there was no access to the cryo-console data afterwards. Nevertheless, the 
registry enrolled an important number of patients and showed real-life data for each 
application. There are confounding variables that were not included in the model. The grade
of the occlusion and the vein diameter were pointed out by Gosh et al. [9] as independent 
predictors of AF recurrence, but the present registry lacked those data. Moreover, another 
confounding factor is if the “pull-down” technique for achieving isolation was 
implemented. Those applications would reach a lower NT than predicted by the present 
model.
Conclusions
Freezing rate is an early predictor of the quality of a CB application. A time to reach
–30°C after 40–50 s should prompt termination of the freeze application. The time to –30°C
is closely related to balloon NT which is a well-established predictor of vein reconnection 
and AF recurrence. 
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Table 1. Baseline characteristics of all patients included in the analysis. 
Baseline characteristic Overall (n = 
1733)
Age [years] 58.01 ± 10.41
Male sex 1202 (68.9%)
Weight [kg] 83,3 ± 15,52
13
Height [cm] 171.7 ± 10.24
Body mass index [kg/m2] 28.0 ± 3.9
Atrial fibrillation type:
      Paroxysmal 1235 (71.2%)
      Persistent 432 (24.9%)
      Long-standing 37 (2.1%)
      Short-standing 31 (1.8%)
Repeat procedure 80 (4.6%)
Heart disease 327 (18.9%)
Left-side pulmonary veins anatomy:
      2 veins 1448 (83.4%)
      > 2 veins 5 (0.3%)
      Common trunk 264 (15.2%)
Right-side pulmonary veins anatomy:
      2 veins 1571 (90.4%)
      > 2 veins 114 (6.6%)
      Common trunk 28 (1.6%)
Table 2. Odds ratio (OR) for univariate logistic models predicting successful application 
and successful application with time to isolation (TTI) < 60 s.
Endpoint
Predictor† Successful application Successful application and TTI < 60 s
OR AUC (n = 6,414) OR AUC (n = 3,638)
Time to –30°C 
[s]
0.60 0.66 0.43 0.70
Nadir temp [°C] 5.27 0.80* 3.24 0.69
Thaw time [s] 2.23 0.80* 1.53 0.69
*Statistically significant χ2 goodness of fit difference; †Measured in 10-unit steps; AUC 
— area under the curve
 
14
Figure 1. Flowchart and classification of cryoballoon applications. Successful application 
refers to achieving vein isolation; TTI — time to isolation. 
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Figure 2. Multivariate logistic regression models predicting successful application.
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Figure 3. Multivariate logistic regression models predicting a successful cryoballoon 
application achieving vein isolation within 60 s. 
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Figure 4.
Predicted probability of successful application with time to isolation (TTI) under 60 s for 
different times to reach –30°C (s). Data were derived from the logistic models.
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Figure 5. Scatter plot of recorded nadir temperature and time to –30°C; A, B. Green dots 
represent successful applications, and red dots represent failure to isolate; C, D. Green dots 





Figure 6. Multivariable linear regression model for nadir temperature. 
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